KFAR SABA, Israel, Aug. 7, 2019 /CNW/ — CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the successful enrollment and operation of the first two patients in the Agili-C™ Investigational Device Exemption (IDE) pivotal study at Hospital for Special Surgery (HSS), New York, NY . …

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone